{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Biomarker clearance was defined as no detectable ctDNA, CA19-9, or CEA at post-treatment time points","groups":[{"description":"The ctDNA Group included subjects with detectable ctDNA at baseline.","id":"OG000","title":"ctDNA Group"},{"description":"The Serum Tumor Biomarker Group included subjects who did not have detectable ctDNA at baseline, but did have either detectable CA19-9 or CEA.","id":"OG001","title":"Serum Tumor Biomarker Group"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"The Proportion of Participants With Biomarker Clearance by Biomarker Type","type":"SECONDARY","unitOfMeasure":"Participants"}